L., Charpentier, G., Warren, M
These are similar in magnitude, albeit slightly improved, to the reductions observed for the efficacy estimand for tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in this NMA (mean [95% CrI] weight reduction 3.78% [ 6.99, 3.66], 4.86 [ 8.07, 2.67]
Additionally, it was found that at two years 26 percent of individuals switched GLP-1 drugs during therapy an increase from 11 percent at one year
G., & Anane, E
comparing liraglutide 1.2 mg/day + metformin 1000 mg BID combination therapy and liraglutide 1.2 mg/day alone in nondiabetic women with PCOS and obesity, again despite a significant improvement in anthropometric parameters in both groups, the combined therapy was associated with a significant reduction in fasting and 120 min glucose levels during OGTT [60]